The Dato-DXd is based on the TROPION-Breast01, a phase 3 study comparing the physicians’ choice among patients with ER-positive, HER2-low or HER2-negative metastatic breast cancer who have had ...

Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC ... TNBC and HR-positive, HER2-low or negative breast cancer. The programme includes seven phase III trials in lung cancer ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

Datopotamab deruxtecan (Dato-DXd) Datopotamab deruxtecan (Dato-DXd ... TNBC and HR-positive, HER2-low or negative breast cancer. The programme includes seven Phase III trials in lung cancer and five ...

Dato-DXd: Daiichi Sankyo, Inc. Datopotamab deruxtecan (Dato-DXd) is an investigational currently in Phase III for HR-positive ...

Datopotamab deruxtecan – also known as Dato-DXd – has already shown efficacy in triple-negative breast cancer (TNBC) in TROPION-PanTumor01, and the new cohort could extend the eligible patient ...

It found a median PFS of 6.9 months for Dato-DXd vs 4.9 months for chemo. “Despite marked progress in the treatment of HR-positive, HER2-negative breast cancer, most patients with advanced ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Next slide. Now we're going to move on to Dato-DXd Breast Cancer Program, TROPION-Breast01 clinical trial. This is a study that was conducted in HR Hormone receptor-positive breast cancer patients ...